Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease
Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with tho...
Gespeichert in:
| Veröffentlicht in: | Circulation Journal 2010, Vol.74(3), pp.442-448 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 448 |
|---|---|
| container_issue | 3 |
| container_start_page | 442 |
| container_title | Circulation Journal |
| container_volume | 74 |
| creator | Kim, Sung Soo Hong, Young Joon Jeong, Myung Ho Kim, Weon Kim, Hyun-Kuk Ko, Jum Suk Lee, Min Goo Sim, Doo Sun Park, Keun Ho Yoon, Nam Sik Yoon, Hyun Ju Kim, Kye Hun Park, Hyung Wook Kim, Ju Han Ahn, Youngkeun Cho, Jeong Gwan Park, Jong Chun Song, Sun-Jung Cho, Dong Lyun Kang, Jung Chaee |
| description | Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0±1.6 mm2 vs +3.4±1.7 mm2, P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group. Conclusions: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome. (Circ J 2010; 74: 442 - 448) |
| doi_str_mv | 10.1253/circj.CJ-09-0674 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733558907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733558907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-6d05e88d451032fa39ca58ed1f7b36b61ea542fb6a2de58004ab216782bde25f3</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi0EoqVw54R84-Ti-COJj6tAaatKRaIIcbImzoR6lcSL7RXsv6-3u7SXmZH1zKPxS8j7ip9XQstPzke3Pu-uGTeM1416QU4rqRqmWsFfPs41M62SJ-RNSmvOheHavCYngldcmoafkunub2C_ECLtJr94BxO93WYXZqSrMWOkq975f36GnnUBMg70e8Yl06t5M8GSIfuwUL_Qb2Uq74n-9PmediGGBeKOrmJx7OhnnxASviWvRpgSvjv2M_Lj4stdd8lubr9edasb5pSRmdUD19i2g9LlSjGCNA50i0M1Nr2s-7pC0EqMfQ1iQN1yrqAXVd20oh9Q6FGekY8H7yaGP1tM2c4-OZzKxRi2yTZSat0a3hSSH0gXQ0oRR7uJ5bNxZytu9xHbx4htd225sfuIy8qHo3zbzzg8LfzPtAAXB2CdMvzGJwBi9m7Co7FRVu7Ls_kZuIdocZEP9BWSjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733558907</pqid></control><display><type>article</type><title>Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease</title><source>J-STAGE (Free - Japanese)</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Kim, Sung Soo ; Hong, Young Joon ; Jeong, Myung Ho ; Kim, Weon ; Kim, Hyun-Kuk ; Ko, Jum Suk ; Lee, Min Goo ; Sim, Doo Sun ; Park, Keun Ho ; Yoon, Nam Sik ; Yoon, Hyun Ju ; Kim, Kye Hun ; Park, Hyung Wook ; Kim, Ju Han ; Ahn, Youngkeun ; Cho, Jeong Gwan ; Park, Jong Chun ; Song, Sun-Jung ; Cho, Dong Lyun ; Kang, Jung Chaee</creator><creatorcontrib>Kim, Sung Soo ; Hong, Young Joon ; Jeong, Myung Ho ; Kim, Weon ; Kim, Hyun-Kuk ; Ko, Jum Suk ; Lee, Min Goo ; Sim, Doo Sun ; Park, Keun Ho ; Yoon, Nam Sik ; Yoon, Hyun Ju ; Kim, Kye Hun ; Park, Hyung Wook ; Kim, Ju Han ; Ahn, Youngkeun ; Cho, Jeong Gwan ; Park, Jong Chun ; Song, Sun-Jung ; Cho, Dong Lyun ; Kang, Jung Chaee</creatorcontrib><description>Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0±1.6 mm2 vs +3.4±1.7 mm2, P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group. Conclusions: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome. (Circ J 2010; 74: 442 - 448)</description><identifier>ISSN: 1346-9843</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.CJ-09-0674</identifier><identifier>PMID: 20103970</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Abciximab ; Aged ; Angioplasty, Balloon, Coronary - mortality ; Antibodies, Monoclonal - therapeutic use ; Coronary Artery Disease - diagnostic imaging ; Coronary Artery Disease - mortality ; Coronary Artery Disease - therapy ; Coronary Restenosis - mortality ; Coronary Restenosis - prevention & control ; Coronary Thrombosis - mortality ; Coronary Thrombosis - prevention & control ; Death, Sudden, Cardiac - epidemiology ; Death, Sudden, Cardiac - prevention & control ; Disease-Free Survival ; Drug-Eluting Stents - statistics & numerical data ; Female ; Follow-Up Studies ; Humans ; Immunoglobulin Fab Fragments - therapeutic use ; Incidence ; Kaplan-Meier Estimate ; Male ; Metals ; Middle Aged ; Platelet Aggregation Inhibitors - therapeutic use ; Prospective Studies ; Restenosis ; Stents ; Thrombosis ; Treatment Outcome ; Ultrasonography, Interventional</subject><ispartof>Circulation Journal, 2010, Vol.74(3), pp.442-448</ispartof><rights>2010 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-6d05e88d451032fa39ca58ed1f7b36b61ea542fb6a2de58004ab216782bde25f3</citedby><cites>FETCH-LOGICAL-c493t-6d05e88d451032fa39ca58ed1f7b36b61ea542fb6a2de58004ab216782bde25f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1876,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20103970$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Sung Soo</creatorcontrib><creatorcontrib>Hong, Young Joon</creatorcontrib><creatorcontrib>Jeong, Myung Ho</creatorcontrib><creatorcontrib>Kim, Weon</creatorcontrib><creatorcontrib>Kim, Hyun-Kuk</creatorcontrib><creatorcontrib>Ko, Jum Suk</creatorcontrib><creatorcontrib>Lee, Min Goo</creatorcontrib><creatorcontrib>Sim, Doo Sun</creatorcontrib><creatorcontrib>Park, Keun Ho</creatorcontrib><creatorcontrib>Yoon, Nam Sik</creatorcontrib><creatorcontrib>Yoon, Hyun Ju</creatorcontrib><creatorcontrib>Kim, Kye Hun</creatorcontrib><creatorcontrib>Park, Hyung Wook</creatorcontrib><creatorcontrib>Kim, Ju Han</creatorcontrib><creatorcontrib>Ahn, Youngkeun</creatorcontrib><creatorcontrib>Cho, Jeong Gwan</creatorcontrib><creatorcontrib>Park, Jong Chun</creatorcontrib><creatorcontrib>Song, Sun-Jung</creatorcontrib><creatorcontrib>Cho, Dong Lyun</creatorcontrib><creatorcontrib>Kang, Jung Chaee</creatorcontrib><title>Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0±1.6 mm2 vs +3.4±1.7 mm2, P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group. Conclusions: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome. (Circ J 2010; 74: 442 - 448)</description><subject>Abciximab</subject><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary - mortality</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary Artery Disease - mortality</subject><subject>Coronary Artery Disease - therapy</subject><subject>Coronary Restenosis - mortality</subject><subject>Coronary Restenosis - prevention & control</subject><subject>Coronary Thrombosis - mortality</subject><subject>Coronary Thrombosis - prevention & control</subject><subject>Death, Sudden, Cardiac - epidemiology</subject><subject>Death, Sudden, Cardiac - prevention & control</subject><subject>Disease-Free Survival</subject><subject>Drug-Eluting Stents - statistics & numerical data</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Incidence</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Metals</subject><subject>Middle Aged</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prospective Studies</subject><subject>Restenosis</subject><subject>Stents</subject><subject>Thrombosis</subject><subject>Treatment Outcome</subject><subject>Ultrasonography, Interventional</subject><issn>1346-9843</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhi0EoqVw54R84-Ti-COJj6tAaatKRaIIcbImzoR6lcSL7RXsv6-3u7SXmZH1zKPxS8j7ip9XQstPzke3Pu-uGTeM1416QU4rqRqmWsFfPs41M62SJ-RNSmvOheHavCYngldcmoafkunub2C_ECLtJr94BxO93WYXZqSrMWOkq975f36GnnUBMg70e8Yl06t5M8GSIfuwUL_Qb2Uq74n-9PmediGGBeKOrmJx7OhnnxASviWvRpgSvjv2M_Lj4stdd8lubr9edasb5pSRmdUD19i2g9LlSjGCNA50i0M1Nr2s-7pC0EqMfQ1iQN1yrqAXVd20oh9Q6FGekY8H7yaGP1tM2c4-OZzKxRi2yTZSat0a3hSSH0gXQ0oRR7uJ5bNxZytu9xHbx4htd225sfuIy8qHo3zbzzg8LfzPtAAXB2CdMvzGJwBi9m7Co7FRVu7Ls_kZuIdocZEP9BWSjQ</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Kim, Sung Soo</creator><creator>Hong, Young Joon</creator><creator>Jeong, Myung Ho</creator><creator>Kim, Weon</creator><creator>Kim, Hyun-Kuk</creator><creator>Ko, Jum Suk</creator><creator>Lee, Min Goo</creator><creator>Sim, Doo Sun</creator><creator>Park, Keun Ho</creator><creator>Yoon, Nam Sik</creator><creator>Yoon, Hyun Ju</creator><creator>Kim, Kye Hun</creator><creator>Park, Hyung Wook</creator><creator>Kim, Ju Han</creator><creator>Ahn, Youngkeun</creator><creator>Cho, Jeong Gwan</creator><creator>Park, Jong Chun</creator><creator>Song, Sun-Jung</creator><creator>Cho, Dong Lyun</creator><creator>Kang, Jung Chaee</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease</title><author>Kim, Sung Soo ; Hong, Young Joon ; Jeong, Myung Ho ; Kim, Weon ; Kim, Hyun-Kuk ; Ko, Jum Suk ; Lee, Min Goo ; Sim, Doo Sun ; Park, Keun Ho ; Yoon, Nam Sik ; Yoon, Hyun Ju ; Kim, Kye Hun ; Park, Hyung Wook ; Kim, Ju Han ; Ahn, Youngkeun ; Cho, Jeong Gwan ; Park, Jong Chun ; Song, Sun-Jung ; Cho, Dong Lyun ; Kang, Jung Chaee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-6d05e88d451032fa39ca58ed1f7b36b61ea542fb6a2de58004ab216782bde25f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Abciximab</topic><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary - mortality</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary Artery Disease - mortality</topic><topic>Coronary Artery Disease - therapy</topic><topic>Coronary Restenosis - mortality</topic><topic>Coronary Restenosis - prevention & control</topic><topic>Coronary Thrombosis - mortality</topic><topic>Coronary Thrombosis - prevention & control</topic><topic>Death, Sudden, Cardiac - epidemiology</topic><topic>Death, Sudden, Cardiac - prevention & control</topic><topic>Disease-Free Survival</topic><topic>Drug-Eluting Stents - statistics & numerical data</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Incidence</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Metals</topic><topic>Middle Aged</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prospective Studies</topic><topic>Restenosis</topic><topic>Stents</topic><topic>Thrombosis</topic><topic>Treatment Outcome</topic><topic>Ultrasonography, Interventional</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Sung Soo</creatorcontrib><creatorcontrib>Hong, Young Joon</creatorcontrib><creatorcontrib>Jeong, Myung Ho</creatorcontrib><creatorcontrib>Kim, Weon</creatorcontrib><creatorcontrib>Kim, Hyun-Kuk</creatorcontrib><creatorcontrib>Ko, Jum Suk</creatorcontrib><creatorcontrib>Lee, Min Goo</creatorcontrib><creatorcontrib>Sim, Doo Sun</creatorcontrib><creatorcontrib>Park, Keun Ho</creatorcontrib><creatorcontrib>Yoon, Nam Sik</creatorcontrib><creatorcontrib>Yoon, Hyun Ju</creatorcontrib><creatorcontrib>Kim, Kye Hun</creatorcontrib><creatorcontrib>Park, Hyung Wook</creatorcontrib><creatorcontrib>Kim, Ju Han</creatorcontrib><creatorcontrib>Ahn, Youngkeun</creatorcontrib><creatorcontrib>Cho, Jeong Gwan</creatorcontrib><creatorcontrib>Park, Jong Chun</creatorcontrib><creatorcontrib>Song, Sun-Jung</creatorcontrib><creatorcontrib>Cho, Dong Lyun</creatorcontrib><creatorcontrib>Kang, Jung Chaee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Sung Soo</au><au>Hong, Young Joon</au><au>Jeong, Myung Ho</au><au>Kim, Weon</au><au>Kim, Hyun-Kuk</au><au>Ko, Jum Suk</au><au>Lee, Min Goo</au><au>Sim, Doo Sun</au><au>Park, Keun Ho</au><au>Yoon, Nam Sik</au><au>Yoon, Hyun Ju</au><au>Kim, Kye Hun</au><au>Park, Hyung Wook</au><au>Kim, Ju Han</au><au>Ahn, Youngkeun</au><au>Cho, Jeong Gwan</au><au>Park, Jong Chun</au><au>Song, Sun-Jung</au><au>Cho, Dong Lyun</au><au>Kang, Jung Chaee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>74</volume><issue>3</issue><spage>442</spage><epage>448</epage><pages>442-448</pages><issn>1346-9843</issn><eissn>1347-4820</eissn><abstract>Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0±1.6 mm2 vs +3.4±1.7 mm2, P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group. Conclusions: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome. (Circ J 2010; 74: 442 - 448)</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>20103970</pmid><doi>10.1253/circj.CJ-09-0674</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-9843 |
| ispartof | Circulation Journal, 2010, Vol.74(3), pp.442-448 |
| issn | 1346-9843 1347-4820 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733558907 |
| source | J-STAGE (Free - Japanese); MEDLINE; EZB Electronic Journals Library |
| subjects | Abciximab Aged Angioplasty, Balloon, Coronary - mortality Antibodies, Monoclonal - therapeutic use Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - mortality Coronary Artery Disease - therapy Coronary Restenosis - mortality Coronary Restenosis - prevention & control Coronary Thrombosis - mortality Coronary Thrombosis - prevention & control Death, Sudden, Cardiac - epidemiology Death, Sudden, Cardiac - prevention & control Disease-Free Survival Drug-Eluting Stents - statistics & numerical data Female Follow-Up Studies Humans Immunoglobulin Fab Fragments - therapeutic use Incidence Kaplan-Meier Estimate Male Metals Middle Aged Platelet Aggregation Inhibitors - therapeutic use Prospective Studies Restenosis Stents Thrombosis Treatment Outcome Ultrasonography, Interventional |
| title | Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T15%3A27%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two-Year%20Clinical%20Outcome%20After%20Abciximab-Coated%20Stent%20Implantation%20in%20Patients%20With%20Coronary%20Artery%20Disease&rft.jtitle=Circulation%20Journal&rft.au=Kim,%20Sung%20Soo&rft.date=2010-03-01&rft.volume=74&rft.issue=3&rft.spage=442&rft.epage=448&rft.pages=442-448&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.CJ-09-0674&rft_dat=%3Cproquest_cross%3E733558907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733558907&rft_id=info:pmid/20103970&rfr_iscdi=true |